Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 237

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 237
---
,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(47,078,070) 
    $(8,976,315) 
    $(38,101,755) 
     424.5%

Research and Development Expenses

Research and development
expenses were $8,048,000 for the nine months ended September 30, 2025 as compared to $6,157,000 for the nine months ended September 30,
2024, reflecting an increase of $1,891,000. The increase was primarily attributable to an increase in clinical expenses of $2,564,000,
an increase in scientific consulting fees of $706,000 and an increase in drug manufacturing costs of $276,000. In the first quarter of
2025, we began clinical trials related to the IND for CER-1236. This increase was primarily offset by a decrease in lab expenses of $481,000
primarily attributable to a decrease in toxicology studies performed in the 2025 period as compared to the 2024 period, a decrease in
research and development salaries and benefits of approximately $973,000 which included a decrease in stock-based compensation expense
of $775,000 primarily attributable to a decrease in accretion in stock-based option expense and a decrease in other development salaries
and benefits of $198,000, a decrease in depreciation expense of $120,000 and a decrease in other research and development costs of $81,000.

The Company anticipates
that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted
services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used
in clinical development.

General and Administrative Expenses

General and administrative expenses were $5,989,000 for the nine months
ended September 30, 2025 as compared to $7,946,000 for the nine months ended September 30, 2024, reflecting a decrease of $1,957,000.
The decrease during the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024, was primarily due
to a decrease of $1,750,000 in underwriting fees from the PBAX initial public offering, which were incurred upon the consummation of the
business combination in February 2024, a decrease in professional fees of $343,000 attributable